Ro 32-3555 inhibits MMPs, enzymes that degrade extracellular matrix components, thus having potential therapeutic applications in cancer and chronic inflammatory diseases. It targets collagenases 1, collagenases 2, collagenases 3, gelatinase A, gelatinase B, and stromelysins 1.
Ro 32-3555 is utilized in rheumatoid arthritis studies for its potential to prevent joint destruction by inhibiting collagen-degrading matrix metalloproteinases.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
